Biomedicine & Pharmacotherapy (Jul 2022)

Phage delivered CRISPR-Cas system to combat multidrug-resistant pathogens in gut microbiome

  • Arijit Nath,
  • Rahul Bhattacharjee,
  • Aditya Nandi,
  • Adrija Sinha,
  • Sulagna Kar,
  • Nikita Manoharan,
  • Shirsajit Mitra,
  • Abhik Mojumdar,
  • Pritam Kumar Panda,
  • Swadheena Patro,
  • Ateet Dutt,
  • Rajeev Ahuja,
  • Suresh K. Verma,
  • Mrutyunjay Suar

Journal volume & issue
Vol. 151
p. 113122

Abstract

Read online

The Host-microbiome interactions that exist inside the gut microbiota operate in a synergistic and abnormal manner. Additionally, the normal homeostasis and functioning of gut microbiota are frequently disrupted by the intervention of Multi-Drug Resistant (MDR) pathogens. CRISPR-Cas (CRISPR-associated protein with clustered regularly interspersed short palindromic repeats) recognized as a prokaryotic immune system has emerged as an effective genome-editing tool to edit and delete specific microbial genes for the expulsion of bacteria through bactericidal action. In this review, we demonstrate many functioning CRISPR-Cas systems against the anti-microbial resistance of multiple pathogens, which infiltrate the gastrointestinal tract. Moreover, we discuss the advancement in the development of a phage-delivered CRISPR-Cas system for killing a gut MDR pathogen. We also discuss a combinatorial approach to use bacteriophage as a delivery system for the CRISPR-Cas gene for targeting a pathogenic community in the gut microbiome to resensitize the drug sensitivity. Finally, we discuss engineered phage as a plausible potential option for the CRISPR-Cas system for pathogenic killing and improvement of the efficacy of the system.

Keywords